Crossmark

Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors

Crossref DOI link: https://doi.org/10.1007/s00018-024-05353-6

Published Online: 2024-09-10

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Egger, Klemens https://orcid.org/0000-0001-5072-9674
Aicher, Helena D. https://orcid.org/0000-0001-5915-7086
Cumming, Paul https://orcid.org/0000-0002-0257-9621
Scheidegger, Milan https://orcid.org/0000-0003-1313-2208
Funding

Funding for this research was provided by:

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030-204978)

University of Zurich
License Information

Text and Data Mining valid from 2024-09-10

Version of Record valid from 2024-09-10
More Information

Article History

Received: 16 April 2024

Revised: 19 June 2024

Accepted: 4 July 2024

First Online: 10 September 2024

Declarations

:

: MS co-founded Reconnect Labs, an academic spin-off at the University of Zurich. KE, HDA and PC have no relevant financial or non-financial interests to disclose.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below